Filing Flows › Coya Therapeutics (COYA) › Q4 2025
Coya Therapeutics (COYA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
Coya Therapeutics (COYA) reported revenue of $4.0M for the fourth quarter 2025 (Q4 2025), up 2,029-fold from a year earlier and +11% from the quarter before. Operating margin was -152.3%, net loss $5.7M (144.2% of revenue).
Coya Therapeutics, Q4 2025: revenue $4.0M (2,029× year over year), operating margin -152.3%, net loss $5.7M, operating cash flow −$1.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | +11% | 2,029× |
| Operating profit | −$6.0M | — | — |
| Net earnings | −$5.7M | — | — |
| Operating cash flow | −$1.0M | — | — |
What changed
Revenue was $4.0M in Q4 2025, up 202769% year over year and up 11% from the previous quarter.
Operating costs exceeded revenue by $6.0M, an operating margin of -152.3%. Total costs grew 145% against revenue growth of 202769%. The fastest-growing cost line was Research & development (+155%). The quarter ended with a net loss of $5.7M, wider than the previous quarter's $2.1M loss.
Operating cash flow was −$1.0M. Non-cash charges added back $7K of depreciation and $1.1M of share-based compensation. Working capital and other items added $3.6M.
Questions
What was Coya Therapeutics' revenue in the fourth quarter 2025?
Coya Therapeutics (COYA) reported revenue of $4.0M for the fourth quarter 2025 (Q4 2025), up 2,029-fold from a year earlier and +11% from the quarter before.
Was Coya Therapeutics profitable in the fourth quarter 2025?
Operating loss was $6.0M (-152.3% of revenue) and net loss $5.7M.
Source: Coya Therapeutics 10-K on SEC EDGAR.